NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 1 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,000 | -16.7% | 9,191 | +102.1% | 0.00% | – |
| Q2 2023 | $12,000 | -14.3% | 4,547 | +30.3% | 0.00% | – |
| Q1 2023 | $14,000 | -50.0% | 3,490 | -37.0% | 0.00% | – |
| Q4 2022 | $28,000 | -31.7% | 5,542 | +73.5% | 0.00% | – |
| Q3 2022 | $41,000 | +355.6% | 3,195 | +353.2% | 0.00% | – |
| Q2 2022 | $9,000 | -75.0% | 705 | -69.5% | 0.00% | – |
| Q1 2022 | $36,000 | -64.0% | 2,314 | -59.3% | 0.00% | – |
| Q4 2021 | $100,000 | +66.7% | 5,687 | +96.4% | 0.00% | – |
| Q3 2021 | $60,000 | +39.5% | 2,895 | +34.2% | 0.00% | – |
| Q2 2021 | $43,000 | -10.4% | 2,157 | +30.7% | 0.00% | – |
| Q1 2021 | $48,000 | -99.6% | 1,650 | -99.8% | 0.00% | -100.0% |
| Q1 2020 | $11,516,000 | -33.4% | 933,959 | -0.2% | 0.01% | 0.0% |
| Q4 2019 | $17,301,000 | +3.4% | 935,675 | -22.6% | 0.01% | -14.3% |
| Q3 2019 | $16,735,000 | -5.4% | 1,208,367 | -0.0% | 0.01% | 0.0% |
| Q2 2019 | $17,691,000 | – | 1,208,433 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |